Roche agrees to buy PathAI for up to $1.05 billion
Updated
Updated · The Wall Street Journal · May 7
Roche agrees to buy PathAI for up to $1.05 billion
13 articles · Updated · The Wall Street Journal · May 7
The Swiss drugmaker will pay $750 million upfront for the U.S.-based company, with up to $300 million more tied to targets, and expects the deal to close in the second half.
Roche said the acquisition builds on the companies' 2021 partnership and brings in-house an AI pathology platform designed to streamline diagnostic workflows and support clinical-therapy development.
The group plans to scale PathAI's technology globally for pathology labs and biopharma, combining it with its own diagnostics business to improve laboratory efficiency and aid drug-target and diagnostic discovery.
Roche is betting a billion dollars on AI, but will this technology actually make new medicines faster or cheaper to approve?
As new AI laws take effect, can Roche's pathology acquisition avoid the regulatory and ethical pitfalls that threaten medical innovation?
Can AI pathology tools mislead doctors more than they help, creating a dangerous 'plausibility trap' for cancer diagnoses?